Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans
Retrieved on:
Wednesday, December 15, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, CRISPR, Company, Participation, Securities Act of 1933, Genome, Business, Executive, Corporate development, ASDP Indonesia Ferry, Nasdaq, PKMYT1, ATR, Security (finance), DNA, Legislation, Mission statement, View, Online gambling, Pharmaceutical industry, Reparations for slavery
Under U.S. and Canadian securities laws and the Companys trading policies, insiders of Repare are subject to limits on their ability to sell shares in the Company.
Key Points:
- Under U.S. and Canadian securities laws and the Companys trading policies, insiders of Repare are subject to limits on their ability to sell shares in the Company.
- Up to 328,681 common shares of Repare may be sold under the ASDPs implemented or modified by the Executives in the aggregate, and up to 95,320 common shares of Repare may be sold under the ASDPs implemented by the Other Insiders.
- Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
- SNIPRx is a registered trademark of Repare Therapeutics Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215006112/en/